荣昌生物：维迪西妥单抗新适应症获批上市

Core Viewpoint - Rongchang Biopharmaceutical has received approval from the National Medical Products Administration for the registration certificate of Vidisicimab (brand name: Aidiqi) for a new indication to treat HER2 low-expressing breast cancer with liver metastasis [1] Group 1 - Vidisicimab is now approved for its fourth indication in China [1] - The drug is indicated for adult patients with unresectable or metastatic HER2 low-expressing breast cancer (IHC 1+ or IHC 2+/ISH-) who have previously received at least one systemic treatment during the metastatic disease stage or have relapsed within 12 months after adjuvant chemotherapy [1]